INHERITED DYSLIPIDAEMIC DISORDERS CONTRIBUTING TO CORONARY HEART DISEASE

Authors

  • Salma Attaullah
  • Rahim Bangash
  • Aman ullah
  • Zahoor Ahmed
  • Jamilur Rehman

Abstract

Background: Lipoprotein (a) [Lp (a)] is an established independent risk factor for prematuremyocardial infarction (MI)/coronary artery disease (CAD). The study was conducted to determine thevalue of Lp (a) in prediction of CAD or MI in the offspring at risk. Methods: A total of 160 subjectswere investigated. Serum Lp (a) was measured by ELISA, serum total cholesterol, triglycerides (TG)and HDL-Cholesterol by enzymatic colorimetric methods using standard kits. Results: Differences inlevels of total Lp (a) and cholesterol were observed between patients and controls. Both Lp (a)(16.23±1.95 mg/dL) and cholesterol (175.00±7.60 mg/dL) of group A (patients) were higher than thecorresponding controls. However an opposite trend in results was noted for serum HDL-Cholesterol inpatients vs. controls. Conclusion: Persons found to have elevated levels of Lp (a) should focus oncontrolling the known modifiable risk factor for heart disease, especially smoking,hypercholesterolemia, obesity, hypertension and sedentary life style.Keywords: Dyslipidaemia, Coronary Artery Disease, CAD, Lipoprotein (a), MyocardialInfarction, MI, Cholesterol, HDL-Cholesterol, LDL-Cholesterol, Triglycerides

References

Rallidis LS, Papageorgakis NJ, Maglou AA, Exadactylos NJ,

Tsitouris GK, Papasteriadis EG. High incidence of

dyslipdaemia in the offspring of Greek man with premature

coronary artery disease. Eur Heart J 1998;19:395–401.

Robert S. Inherited disorder contributing to coronary heart

disease. Disease Inst 1996;2:876–83.

Backer GD, Henauw SD, Sans S, Nicaud V, Masana L,

Visvikis S. A comparison of lifestyle, genetic, bioclinical and

biochemical variables of offspring with and without family

histories of premature coronary heart disease: The experience

of the European Atherosclerosis Research Studies. J

Cardiovascular Risk 1999;6:183–8.

Genest Jr JJ, Martin-Muleny SS, McNamara JR, Ordovas

JM, Jennefer J, Mayres RH. Familial lipoprotein disorder in

patients with premature coronary artery disease. Circulation

;85:2025–33.

Srinavasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson

GS. Racial (black–white) differences in serum lipoprotein (a)

distribution and its relation to parental myocardial infraction in

children: Bogalusa Heart Study. Circulation 1991;84:160–167.

Balleul S, Couderc R, Rossignol C, Fermannian J, Boutouchent

F, Farnier, M. Lipoprtein (a) in childhood: Relation with other

atherosclerotic risk factors and family history of

atherosclerosis. Clin Chem 1995;41:241–5.

Ahmad S, Yaqoob Z, Samad A. Acute myocardial infarction

in an eighteen years old Pakistani girl without classical risk

factors for premature coronary artery disease (case report and

review of the literature). PJC 1997;11:1271–80.

Kannel WB, McGee D, Gordon J. A general cardiovascular

risk factor profiles. The Framingham Study. Am J Cardiol

;38:46–51.

J Ayub Med Coll Abbottabad 2008;20(4)

http://www.ayubmed.edu.pk/JAMC/PAST/20-4/Salma.pdf 93

Gensini GF, Comeglio M, Collella A. Classical risk factors

and emerging elements in the risk profile for coronary artery

disease. Eur Heart J 1998;19(Suppl A):A53–A61.

Berg K. A new system in man: The Lp (a) system. Acta

Pathol Microbial Scand 1963;59:369–82.

Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Guar

VP. Effect of number of Apolipoprotein (a) Kingle 4

domains on immunochemical measurement of lipoprotein (a).

Clin Chem 1995;41(2):2246–55.

Igarashi Y, Yamura M, Ito M, Inuzuka H, Ojima K, Aziwa

Y. Elevated serum lipoprotein (a) is a risk factor for left

arterial thrombus in patients with chronic arterial fibrillation:

A Tran–esophageal Echocardiographic study. Am Hear J

;136:965–71.

Gaubatz JW, Hoogeveen RC, Hoffman AS. Isolation,

quantitation and characterization of stable complex formed

by Lp (a) binding to triglyceride–rich lipoproteins. J Lipid

Res 2001;42(12):2058–68.

Lippi G, Bassi A, Broco G. Lipoprotein (a) concentration is

not associated with venous thrombo-embolism in case control

study. Haemotologica 1999;84:726–9.

Bostom AG, Shemin D, Verhoef P. Prospective study of

coronary heart disease incidence in relation to fasting total

homocysteine, related genetic polymorphisms, and B–

vitamins: The Atherosclerosis Risk In Communities (ARIC)

Study. Circulation 1998;96:201–7.

Kim H, Marcovina SM, Edwards KL. Lipoprotein (a) as a

risk factor for maternal cardiovascular disease mortality in

Kindreds with familial combined hyperlipidemia or familial

hypertriglyceridaemia. Clin Genet 2001;60(3):188–97.

Friedwald WT, Levy RI, Fredhrickson DS. Estimation of

concentration of low-density lipoprotein cholesterol in

plasma without use of preparative ultracentrifuge. Clin Chem

;18:449–502.

Ahmad MS, Ahmad I. Effect of CAD duration of plasma

lipids and lipoproteins concentration. PJI 1995;5:83–6.

Assmann G, Schulte H. Relation of high–density lipoproteins

and triglycerides to incidence of atherosclerotic coronary

artery disease. (The PROCAM Experience). Am J Cardiol

;733–7.

Wood D. European and American recommendations for Coronary

Heart Disease. Eur Heart J 1998;19(Suppl A):A12–A19.

Robins SJ. Management of Lipid Disorders: A basis and

guide for therapeutic intervention. 1st Ed. Baltimore,

Williams and Wilkins, 1997;42:52–3.

Wong MS, Chew WLS, Aw TC. Serum Lipoprotein (a)

profile in Singaporean population. Patho 1997;31:225–9.

Angles C. Structural basis for the Pathophysiology of

Lipoprotein (a) in the atherothrombotic process. Braz J Med

Bio Res 1997;11:1271–80.

Rossl A, Baldo–Enzi G, Ganzaroli C, Coscetti G.

Relationship of early Carotid Artery disease with Lipoprotein

(a), Apolipoprotein B, and Fibrinogen in asymptomatic

essential hypertensive patients and normotensive subjects. J

Investig Med 2001;49(6):505–13.

Craig WY, Nevenux LM, Palomaki GF, Cleveland MM,

Haddo JE. Lipoprotein (a) as a risk factor for ischemic heart

disease: Meta–analysis of prospective studies. Clin Chem

;44:2301–6.

Hegele RA, Freeman MR, Langer A, Connelly PW,

Amstrong PW. Acure reduction of Lipoprotein (a) by tissue–

type plasminogen activator. Circ 1992;85:2034–8.

Vella JC, Jover Vega GL, Denke MA, Grundy SM.

Metabolic basis of primary relation of lipoprotein (a) in 11–

years old adolescents to parental cardiovascular heart

disease. Clin Chem 1993;39(3):477–80.

Published

2008-12-01

Most read articles by the same author(s)